Scarica l'app Stockscreener
5.76
0.17%
-0.010
Dopo l'orario di chiusura:
5.81
0.05
+0.87%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Savara Inc Borsa (SVRA) Ultime notizie
The Bull Case For Savara (SVRA) Could Change Following Exclusive MOLBREEVI Distribution Deal With PANTHERx - simplywall.st
Will Savara Inc. stock outperform tech sector in 20252025 Price Momentum & Daily Price Action Insights - ulpravda.ru
How Savara Inc. (YB4P) stock compares with top peersProduct Launch & Technical Confirmation Alerts - ulpravda.ru
PANTHERx® Rare Selected by Savara as the U.S. Exclusive Specialty Pharmacy for MOLBREEVI - PharmiWeb.com
How Savara Inc. stock compares to growth peers2025 Institutional Moves & AI Optimized Trading Strategy Guides - ulpravda.ru
How Savara Inc. stock benefits from global expansionJuly 2025 Outlook & High Return Stock Watch Alerts - ulpravda.ru
PANTHERx® Rare Selected by Savara as the U.S. Exclusive Specialty Pharmacy for MOLBREEVI* - Yahoo Finance
Will Savara Inc. (YB4P) stock rise with strong economyBuy Signal & Fast Exit Strategy with Risk Control - ulpravda.ru
Will Savara Inc. stock reach all time highs in 20252025 Market Sentiment & Safe Investment Capital Preservation Plans - ulpravda.ru
Aug Volume: How Savara Inc stock compares to growth peersRisk Management & Growth Focused Investment Plans - moha.gov.vn
Will Savara Inc. stock benefit from sector rotation2026 world cup usa national team group stage key players transition play expert forecast insights - ulpravda.ru
Oppenheimer Assumes Coverage of Savara (SVRA) With an Outperform Rating - MSN
FDA Clock Restarts: Savara Refiles MOLBREEVI for Rare Lung Disease - MyChesCo
Savara (NASDAQ:SVRA) Shares Down 5.1%Should You Sell? - MarketBeat
Savara Inc. (NASDAQ:SVRA) Short Interest Up 33.1% in December - MarketBeat
Death Cross: Is Savara Inc stock a defensive play in 2025Market Growth Summary & Safe Capital Growth Plans - moha.gov.vn
Savara Heads to JPMorgan Conference as Investors Watch Rare Lung Drug - MyChesCo
With 37% Ownership in Savara Inc. (NASDAQ:SVRA), Institutional Investors Have a Lot Riding on the Business - 富途牛牛
Swedbank AB Takes $1.96 Million Position in Savara Inc. $SVRA - MarketBeat
Gap Down: Is Savara Inc YB4P stock a buy for dividend portfolios2025 Trade Ideas & AI Based Buy and Sell Signals - moha.gov.vn
How Savara Inc. stock reacts to Fed rate cutsSector Performance Review & Your Free Entry to Smart Investing Starts Here - bollywoodhelpline.com
Savara price target raised to $10 from $8 at HC Wainwright - MSN
Savara Inc. ticks higher amid takeover speculation - MSN
Market Review: How MTEN stock performs in high volatility marketsMarket Trend Report & Accurate Intraday Trade Tips - moha.gov.vn
What is HC Wainwright's Forecast for Savara FY2027 Earnings? - MarketBeat
Savara (SVRA) Stock Price, Quote, News & History - Benzinga
FY2029 Earnings Estimate for Savara Issued By HC Wainwright - MarketBeat
SVRA SEC FilingsSavara Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Savara stock advances as Guggenheim reiterates Buy rating on BLA resubmission By Investing.com - Investing.com South Africa
Savara (SVRA) Receives Revised Buy Rating from HC Wainwright & C - GuruFocus
Savara stock price target raised to $10 from $8 at H.C. Wainwright By Investing.com - Investing.com Nigeria
Savara stock advances as Guggenheim reiterates Buy rating on BLA resubmission - Investing.com Nigeria
Savara stock price target raised to $10 from $8 at H.C. Wainwright - Investing.com Nigeria
How Investors May Respond To Savara (SVRA) Joining S&P Biotech Index After Key MOLBREEVI Patent Win - simplywall.st
Savara resubmits BLA for rare lung disease treatment with new manufacturer - Investing.com Nigeria
Savara (SVRA) Resubmits Molbreevi BLA to FDA for Autoimmune PAP Treatment - GuruFocus
Savara Resubmits Molbreevi Application to FDA for Rare Lung Disease - marketscreener.com
Savara Advances MOLBREEVI Toward Approval as Financing Boost Extends Cash Runway - MSN
Savara resubmits the Biologics License Application to the U.S. Food and Drug Administration for Molbreevi - marketscreener.com
Savara resubmits BLA for rare lung disease treatment with new manufacturer By Investing.com - Investing.com South Africa
Savara : Corporate Presentation - marketscreener.com
Savara Resubmits the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) - Yahoo Finance
Savara Inc.(NasdaqGS: SVRA) added to S&P Biotechnology Select Industry Index - marketscreener.com
Savara Locks In Long-Term Europe Protection for Rare Lung Drug MOLBREEVI - MyChesCo
0.80%
4.56%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):